In 2010, the FDA approved the first CTLA-4 inhibitor for the treatment of metastatic melanoma (8), then, PD-1 inhibitors were approved for the treatment of melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). Here, CTLA4 is linked to non-small cell lung carcinoma.